Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 11/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 11/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1300844 | 0.90 | MET (0.51) | METNQO2MAOBGRIN1GRIN2B | |
| SCHEMBL1301165 | 0.85 | MET (0.45) | METNQO2MAOBMAOAACHE | |
| SCHEMBL13285510 | 0.85 | MET (0.45) | METNQO2MAOBMAOAACHE | |
| SCHEMBL1301051 | 0.81 | GRIN1 (0.41) | GRIN1GRIN2B | |
| SCHEMBL1302048 | 0.81 | GRIN1 (0.41) | GRIN1GRIN2B | |
| SCHEMBL1301035 | 0.80 | MET (0.52) | METGRIN1GRIN2B | |
| SCHEMBL1300839 | 0.79 | MET (0.50) | METGRIN1GRIN2BCNR2 | |
| SCHEMBL22310734 | 0.74 | MET (0.43) | METNQO2MAOBKDM1AMAOA | |
| SCHEMBL22310322 | 0.74 | MET (0.39) | METNQO2MAOBKDM1AACHE | |
| SCHEMBL22310732 | 0.73 | MET (0.52) | METNQO2MAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877751-B2 | Benzothiazolone derivatives | MERCK PATENT GMBH (DE) | 2014-11-04 | — | — | US | claimed |
| US-20110269756-A1 | BENZOTHIAZOLONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-03 | — | — | US | claimed |
| US-8877751-B2 | Benzothiazolone derivatives | MERCK PATENT GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-8877751-B2 | Benzothiazolone derivatives | MERCK PATENT GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-8877751-B2 | Benzothiazolone derivatives | MERCK PATENT GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20110269756-A1 | BENZOTHIAZOLONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269756-A1 | BENZOTHIAZOLONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269756-A1 | BENZOTHIAZOLONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2373635-A1 | BENZOTHIAZOLONE DERIVATIVE | Merck Patent GmbH (DE) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010078905-A1 | BENZOTHIAZOLONE DERIVATIVE | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010078905-A1 | BENZOTHIAZOLONE DERIVATIVE | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269756-A1 | BENZOTHIAZOLONE DERIVATIVES | RET, JAK2, MET | MET 3/4885NQO2 1035/4885MAOB 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.